MedTrace Logo

Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder

NCT01423838 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2011-08-26

No results posted yet for this study

Summary

Null hypothesis of the trial is that there is no difference between solifenacin and oxybutynin with respect to efficacy, side effects, patient satisfaction and quality of life measures in patients with overactive bladder.

Conditions

Interventions

DRUG

Solifenacin

5 mg, oral, once in a day

DRUG

Oxybutynin

5 mg, oral, three times in a day

Sponsors & Collaborators

  • Kocaeli University

    collaborator OTHER

  • Akdeniz University

    collaborator OTHER

  • Cukurova University

    collaborator OTHER

  • Baskent University

    collaborator OTHER

  • Ankara University

    collaborator OTHER

  • University of Gaziantep

    collaborator OTHER

  • Inonu University

    collaborator OTHER

  • Gaziosmanpasa University

    collaborator UNKNOWN

  • Kahramanmaras Sutcu Imam University

    collaborator OTHER

  • Adana Numune Training and Research Hospital

    lead OTHER_GOV

Principal Investigators

  • Murat Api, M.D., Ph.D. · Turkish Republic Ministry of Health Adana Numune Training and Research Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01423838 on ClinicalTrials.gov